The report
Immediate Safety Actions
- Contact ophthalmology and rheumatology urgently today, and screen immediately for vision loss, amaurosis fugax, diplopia, or focal neurological deficits [14, 26, 27].
- Start prednisolone (or prednisone) 40–60 mg orally once daily immediately if no visual symptoms are present; do not delay treatment for imaging or biopsy [2, 27, 35].
- Administer methylprednisolone 500–1000 mg intravenously once daily for 3 days instead of oral therapy if any visual symptoms or transient visual disturbances are present [2, 12, 27].
- Perform immediate visual acuity, visual field, pupillary (relative afferent pupillary defect), and fundoscopic examinations, alongside temporal artery palpation [6, 27, 29].
Conclusion and Recommendation
Giant cell arteritis (GCA) (cranial phenotype) is the most likely diagnosis with high clinical probability, given the patient's age (>50 years), 3 weeks of jaw claudication, new temporal headache, scalp tenderness, and markedly elevated ESR (88 mm/h) [1, 6, 16]. The immediate glucocorticoid actions above treat suspected GCA as a medical emergency to prevent irreversible arteritic ischaemic optic neuropathy (vision loss) and stroke [10, 11, 20, 26]. Once glucocorticoids are started, arrange urgent confirmatory testing—temporal artery colour duplex ultrasound first-line if expertise is available, or temporal artery biopsy within 1 week—and obtain baseline inflammatory and metabolic bloods [2, 8, 23, 26, 27].
Clinical Dashboard
| Metric | Assessment | Confidence | Critical Action |
|---|---|---|---|
| Primary diagnosis | Cranial giant cell arteritis (GCA) [6, 36] | High | Confirm via ultrasound or biopsy within 1 week [2, 8, 23] |
| Acuity | Critical (vision-threatening emergency) [26] | High | Escalate to IV steroids if vision changes [2, 12] |
| Key risk | Irreversible vision loss (18%) or stroke [11, 30] | High | Ophthalmology review and 24–48 h symptom check [27] |
Differential Diagnosis
| Diagnosis | Estimated probability | Findings for | Findings against | Confirmatory / exclusion test |
|---|---|---|---|---|
| Giant cell arteritis (cranial) | High (>80%) | Age 72, jaw claudication, temporal headache, scalp tenderness, ESR 88 mm/h [1, 6, 16] | Visual/PMR status unstated | Temporal artery ultrasound (halo sign) or biopsy [2, 26] |
| Polymyalgia rheumatica (isolated) | Low–moderate (10–15% without GCA) | Age >50 years, markedly elevated ESR [5, 22] | Jaw claudication, temporal headache, scalp tenderness [5, 22] | Clinical exclusion of GCA; shoulder/hip ultrasound [5, 22, 39] |
| Temporomandibular joint / dental pathology | Low (<5%) | Pain on chewing | True claudication, scalp tenderness, ESR 88 mm/h | Dental/TMJ examination; inflammatory markers |
| Primary headache / trigeminal neuralgia | Low (<5%) | New unilateral temporal pain | Age 72, jaw claudication, ESR 88 mm/h | Clinical criteria; neuroimaging if atypical |
| Intracranial mass / CNS infection | Must-not-miss (<5%) | New headache in older adult | Jaw claudication, scalp tenderness, 3-week course | Urgent CT/MRI brain if focal CNS signs |
Recommended Work-up
- Temporal artery colour duplex ultrasound (bilateral temporal ± axillary arteries): most informative rapid non-invasive test; a halo sign, stenosis, or occlusion confirms GCA and may avoid biopsy [8, 26, 27, 32, 39].
- Temporal artery biopsy (20–30 mm specimen, ideally within 1 week of starting steroids): gold standard (specificity 100%, sensitivity ~77%) if ultrasound is unavailable, equivocal, or negative despite high suspicion [2, 23, 33].
- CRP, full blood count, renal and liver function, glucose, HbA1c: quantifies systemic inflammation (CRP), checks for reactive thrombocytosis/anaemia, and establishes baseline before prolonged glucocorticoids [6, 17].
- Large-vessel imaging (CT angiography, MR angiography, or FDG-PET-CT): reserved for negative cranial testing or extracranial symptoms/bruits to detect large-vessel GCA and baseline aortic dilatation [8, 9, 19].
- Brain CT or MRI: perform only if focal neurological deficits, altered mental status, or atypical features raise concern for stroke or an intracranial mass [10, 11].
Management Plan
- Now: Add gastroprotection (omeprazole 20 mg orally once daily) alongside high-dose glucocorticoids. Consider aspirin 75–100 mg orally once daily only if no bleeding contraindication exists, weighing ischaemic versus bleeding risk.
- Next 24–48 hours: Reassess headache, jaw claudication, and vision within 24–48 hours; rapid symptom improvement supports GCA, whereas any new visual blurring, diplopia, or amaurosis fugax mandates immediate hospital admission and intravenous methylprednisolone [2, 12, 27].
- Disposition: Manage via an urgent same-day outpatient rheumatology and ophthalmology pathway if vision is intact and home monitoring is safe; admit immediately if visual symptoms or systemic instability are present [27].
- Taper and steroid-sparing therapy: Maintain prednisolone 40–60 mg orally once daily until symptoms resolve and ESR/CRP normalise (typically 2–4 weeks), then taper gradually over 12–18 months [2, 12, 30]. Consider early tocilizumab 162 mg subcutaneously once weekly (or upadacitinib 15 mg orally once daily) in patients at high risk of glucocorticoid toxicity or relapse [12, 15, 25, 30].
- Prophylaxis and monitoring: Start calcium/vitamin D and a bisphosphonate (if renal function permits) for glucocorticoid-induced osteoporosis prevention; monitor blood pressure, blood glucose, and lipids.
- Long-term follow-up: Review clinically with ESR/CRP at each taper step (~50% relapse rate) and arrange periodic thoracic aortic imaging for late aneurysm formation [19, 30, 37].
Reasoning and Pitfalls
Granulomatous T-cell and macrophage-mediated inflammation of medium and large cranial arteries drives intimal hyperplasia, luminal occlusion, and end-organ ischaemia (jaw claudication, scalp tenderness or necrosis, optic nerve infarction), alongside an IL-6-mediated acute-phase response (ESR 88 mm/h) [6, 21, 24, 38]. These features satisfy core clinical criteria for GCA with high pre-test probability [1, 3]. Absence of visual loss, diplopia, and focal neurological deficits is assumed and must be verified immediately. The main diagnostic pitfall is delaying glucocorticoids while awaiting biopsy, risking permanent blindness [26, 27]. Switch away from GCA only if both ultrasound and an adequate-length biopsy are negative, symptoms fail to improve within 48–72 hours of high-dose steroids, or imaging identifies an alternative lesion [2, 23, 26].
Information Needed
- Are there any visual symptoms (vision loss, amaurosis fugax, diplopia, blurred vision) or focal neurological deficits? (Determines need for immediate IV methylprednisolone and admission [2, 12, 27]).
- Are the temporal arteries tender, thickened, beaded, or pulseless, and is there any scalp necrosis? (Supports cranial GCA and stratifies vision-loss risk [6, 38]).
- Are there polymyalgia rheumatica symptoms (bilateral shoulder or hip morning stiffness) or constitutional features (fever, weight loss)? (Assesses systemic involvement and overlap [4, 6, 39]).
- Does the patient have diabetes, uncontrolled hypertension, peptic ulcer disease, osteoporosis, or chronic kidney disease? (Guides glucocorticoid-sparing therapy and prophylaxis [11, 25]).
Key Evidence & References
- EULAR 2018 LVV management guideline: start 40–60 mg/day prednisone-equivalent immediately and confirm by imaging or histology. https://pubmed.ncbi.nlm.nih.gov/31270110/ (opens in a new tab)
- ACR/Vasculitis Foundation 2021 guideline: GRADE-based recommendations for GCA diagnosis, glucocorticoid dosing, and steroid-sparing therapy. https://pubmed.ncbi.nlm.nih.gov/34235884/ (opens in a new tab)
- JAMA Intern Med 2020 meta-analysis: diagnostic accuracy of jaw claudication, headache, scalp tenderness, and ESR in GCA. https://pubmed.ncbi.nlm.nih.gov/32804186/ (opens in a new tab)
- EULAR 2018 imaging guideline: recommends early temporal artery ultrasound as first-line imaging in suspected cranial GCA. https://pubmed.ncbi.nlm.nih.gov/29358285/ (opens in a new tab)
- Cochrane 2024 review: temporal artery ultrasound halo sign provides swift, non-invasive diagnosis versus biopsy in GCA emergencies. https://pubmed.ncbi.nlm.nih.gov/38323659/ (opens in a new tab)
- GiACTA trial (NEJM 2017): weekly subcutaneous tocilizumab 162 mg achieves sustained glucocorticoid-free remission in GCA. https://pubmed.ncbi.nlm.nih.gov/28745999/ (opens in a new tab)
- Ann Intern Med 2026 review: vision loss occurs in 18%, ~50% relapse, and patients need long-term aortic aneurysm monitoring. https://pubmed.ncbi.nlm.nih.gov/42114096/ (opens in a new tab)
Dr. Sana
Evidence List
Retrieved from PubMed, NCBI Bookshelf and ClinicalTrials.gov for this question and checked against those databases. 40 articles from 24 journals, 27 in leading general or specialty journals.
- [1] Diagnostic Accuracy of Symptoms, Physical Signs, and Laboratory Tests for Giant Cell Arteritis: A Systematic Review and Meta-analysis (opens in a new tab) — JAMA Intern Med, 2020 · PubMed · Journal site (opens in a new tab) · Free full text (opens in a new tab)
- [2] 2018 Update of the EULAR recommendations for the management of large vessel vasculitis (opens in a new tab) — Ann Rheum Dis, 2020 · PubMed · Journal site (opens in a new tab)
- [3] Headache as the most common manifestation of giant cell arteritis?: a systematic review with meta-analysis (opens in a new tab) — Rheumatol Int, 2025 · PubMed · Journal site (opens in a new tab)
- [4] Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review (opens in a new tab) — JAMA, 2016 · PubMed · Journal site (opens in a new tab)
- [5] Polymyalgia rheumatica (opens in a new tab) — Lancet, 2023 · PubMed · Journal site (opens in a new tab)
- [6] Varicella zoster virus triggers the immunopathology of giant cell arteritis (opens in a new tab) — Curr Opin Rheumatol, 2016 · PubMed · Journal site (opens in a new tab) · Free full text (opens in a new tab)
- [7] Reduction of jaw opening (trismus) in giant cell arteritis (opens in a new tab) — Ann Rheum Dis, 2002 · PubMed · Journal site (opens in a new tab) · Free full text (opens in a new tab)
- [8] EULAR recommendations for the use of imaging in large vessel vasculitis in clinical practice (opens in a new tab) — Ann Rheum Dis, 2018 · PubMed · Journal site (opens in a new tab)
- [9] Large-vessel vasculitis (opens in a new tab) — Lancet, 2025 · PubMed · Journal site (opens in a new tab)
- [10] Polymyalgia rheumatica and giant-cell arteritis (opens in a new tab) — Lancet, 2008 · PubMed · Journal site (opens in a new tab)
- [11] Giant cell arteritis: beyond temporal artery biopsy and steroids (opens in a new tab) — Intern Med J, 2017 · PubMed · Journal site (opens in a new tab)
- [12] 2021 American College of Rheumatology/Vasculitis Foundation Guideline for the Management of Giant Cell Arteritis and Takayasu Arteritis (opens in a new tab) — Arthritis Rheumatol, 2021 · PubMed · Journal site (opens in a new tab) · Free full text (opens in a new tab)
- [13] A glossary of signs and symptoms of giant cell arteritis (opens in a new tab) — Ann Rheum Dis, 2025 · PubMed · Journal site (opens in a new tab)
- [14] Sudden Vision Loss: A Diagnostic Approach (opens in a new tab) — Am Fam Physician, 2025 · PubMed
- [15] A Phase 3 Trial of Upadacitinib for Giant-Cell Arteritis (opens in a new tab) — N Engl J Med, 2025 · PubMed · Journal site (opens in a new tab)
- [16] Does this patient have temporal arteritis? (opens in a new tab) — JAMA, 2002 · PubMed · Journal site (opens in a new tab)
- [17] Respiratory and otolaryngologic manifestations of giant cell arteritis (opens in a new tab) — Clin Exp Rheumatol, 2015 · PubMed
- [18] Risk loci involved in giant cell arteritis susceptibility: a genome-wide association study (opens in a new tab) — Lancet Rheumatol, 2024 · PubMed · Journal site (opens in a new tab) · Free full text (opens in a new tab)
- [19] Large vessel giant cell arteritis (opens in a new tab) — Lancet Rheumatol, 2024 · PubMed · Journal site (opens in a new tab)
- [20] Ischemic optic neuropathy (opens in a new tab) — Prog Retin Eye Res, 2009 · PubMed · Journal site (opens in a new tab)
- [21] New insights into the pathogenesis of giant cell arteritis: are they relevant for precision medicine? (opens in a new tab) — Lancet Rheumatol, 2021 · PubMed · Journal site (opens in a new tab)
- [22] Polymyalgia Rheumatica (opens in a new tab) — N Engl J Med, 2026 · PubMed · Journal site (opens in a new tab)
- [23] Temporal artery biopsy for suspected giant cell arteritis: A mini review (opens in a new tab) — Indian J Ophthalmol, 2023 · PubMed · Journal site (opens in a new tab) · Free full text (opens in a new tab)
- [24] Giant-cell arteritis and polymyalgia rheumatica (opens in a new tab) — Ann Intern Med, 2003 · PubMed · Journal site (opens in a new tab)
- [25] Trial of Tocilizumab in Giant-Cell Arteritis (opens in a new tab) — N Engl J Med, 2017 · PubMed · Journal site (opens in a new tab)
- [26] Halo sign on temporal artery ultrasound versus temporal artery biopsy for giant cell arteritis (opens in a new tab) — Cochrane Database Syst Rev, 2024 · PubMed · Journal site (opens in a new tab) · Free full text (opens in a new tab)
- [27] Giant Cell Arteritis (opens in a new tab) — Klin Monbl Augenheilkd, 2024 · PubMed · Journal site (opens in a new tab)
- [28] Phase 3 Trial of Secukinumab in Polymyalgia Rheumatica (opens in a new tab) — N Engl J Med, 2026 · PubMed · Journal site (opens in a new tab)
- [29] [Optic nerve neuropathy in the course of giant cell arteritis] (opens in a new tab) — Klin Oczna, 2003 · PubMed
- [30] Giant Cell Arteritis (opens in a new tab) — Ann Intern Med, 2026 · PubMed · Journal site (opens in a new tab)
- [31] Circulating interleukin-6 as a biomarker in a randomized controlled trial of modified-release prednisone vs immediate-release prednisolone, in newly diagnosed patients with giant cell arteritis (opens in a new tab) — Int J Rheum Dis, 2019 · PubMed · Journal site (opens in a new tab)
- [32] Role of ultrasonography in the diagnosis of temporal arteritis (opens in a new tab) — Br J Surg, 2010 · PubMed · Journal site (opens in a new tab)
- [33] Temporal artery biopsy in giant cell arteritis: clinical perspectives and histological patterns (opens in a new tab) — Front Med (Lausanne), 2024 · PubMed · Journal site (opens in a new tab) · Free full text (opens in a new tab)
- [34] Medium- and Large-Vessel Vasculitis (opens in a new tab) — Circulation, 2021 · PubMed · Journal site (opens in a new tab)
- [35] Daily and alternate-day corticosteroid regimens in treatment of giant cell arteritis: comparison in a prospective study (opens in a new tab) — Ann Intern Med, 1975 · PubMed · Journal site (opens in a new tab)
- [36] Cranial involvement in giant cell arteritis (opens in a new tab) — Lancet Rheumatol, 2024 · PubMed · Journal site (opens in a new tab)
- [37] Giant cell arteritis (opens in a new tab) — Curr Opin Rheumatol, 2002 · PubMed · Journal site (opens in a new tab)
- [38] Scalp necrosis in giant cell arteritis: case report and review of the relevance of this cutaneous sign of large-vessel vasculitis (opens in a new tab) — J Am Acad Dermatol, 2009 · PubMed · Journal site (opens in a new tab)
- [39] [Inflammatory Muscle Pain: Polymyalgia Rheumatica with or without Large Vessel Vasculitis] (opens in a new tab) — Dtsch Med Wochenschr, 2020 · PubMed · Journal site (opens in a new tab)
- [40] A study of elastic tissue and actinic radiation in "aging," temporal arteritis, polymyalgia rheumatica, and atherosclerosis. The actinic storm in the modern world (opens in a new tab) — J Am Acad Dermatol, 1991 · PubMed · Journal site (opens in a new tab)
- [41] Giant Cell Arteritis (Temporal Arteritis) (opens in a new tab) — StatPearls, 2024 · NCBI Bookshelf
- [42] Rituximab Effect on Decreasing glUcoCorticoid Exposition in PolyMyalgia Rheumatica Patients Recently Diagnosed (opens in a new tab) — Sint Maartenskliniek, 2023 · ClinicalTrials.gov
- [43] Short Term Efficacy of a Starting Dose of 12.5 mg of Prednisone in Polymyalgia Rheumatica Patients (opens in a new tab) — University of Genova, 2009 · ClinicalTrials.gov
- [44] An Efficacy and Safety Study of Tocilizumab (RoActemra/Actemra) in Participants With Giant Cell Arteritis (GCA) (opens in a new tab) — Hoffmann-La Roche, 2013 · ClinicalTrials.gov
- [45] Evaluation of Efficacy and Safety of Sarilumab in Patients With GCA (opens in a new tab) — Sanofi, 2018 · ClinicalTrials.gov
- [46] Hydroxychloroquine in Giant Cell Arteritis (opens in a new tab) — University Hospital, Toulouse, 2002 · ClinicalTrials.gov